Health Canadas classification of peptides depends on intended use, marketing claims, and manufacturing standards
Mounjaro (tirzepatide) is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus
For individuals on a low-carb diet such as the ketogenic diet or other restricted eating plans bananas may not be the ideal choice
Retatrutide is an investigational triple agonist peptide currently under clinical development, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
In this Perspective, we propose that inhibition of ferroptosis by GPx4 provides protective mechanisms against neurodegeneration
Now, between 900,000 and 1.4 million Canadians are currently using a GLP-1 drug to manage weight loss and diabetes, according to a December 2023 national survey from Dalhousie Universitys Agri-Food Analytics Lab in Halifax